Literature DB >> 26071487

Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency.

Walter Bonfig1, Friedrich-Wilhelm Roehl2, Stefan Riedl3, Helmut Günther Dörr4, Markus Bettendorf5, Jürgen Brämswig6, Eckhard Schönau7, Felix Riepe8, Berthold Hauffa9, Reinhard W Holl10, Klaus Mohnike11.   

Abstract

BACKGROUND: Data on blood pressure (BP) in children and adolescents with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency are conflicting in the literature. PATIENTS AND METHODS: BP data of n = 716 children and adolescents (aged 3-18 years) from a national CAH database were analyzed. BP data were adjusted for height and compared to contemporary national reference data. A systolic and diastolic BP above the 95th centile was defined as hypertensive.
RESULTS: Overall prevalence of hypertension was 12.5%. Prevalence of hypertension was higher in younger children than in adolescents (18.5% vs. 4.9%). Until 8 years of age, fludrocortisone dose/m(2)/day correlated significantly with BP in regression analysis (P < 0.0001). BP correlated significantly with body mass index standard deviation score (BMI-SDS) (P < 0.0001), but not with hydrocortisone dose. In patients with salt-wasting CAH, BMI-SDS and BP were significantly higher compared to patients with simple virilising CAH, P < 0.01.
CONCLUSION: Especially young CAH children seem to be at risk for-most likely transient-hypertension, since the prevalence of hypertension decreases with age. In children up to 8 years of age, the used fludrocortisone dose is a significant risk factor for hypertension. Therefore we recommend accurate measurement of BP and careful fludrocortisone dosing in children with CAH. © American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  blood pressure; congenital adrenal hyperplasia; fludrocortisone; hypertension.

Mesh:

Year:  2015        PMID: 26071487     DOI: 10.1093/ajh/hpv087

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  14 in total

1.  Cardiovascular Risk Factors in Children and Adolescents with Congenital Adrenal Hyperplasia.

Authors:  Elham Hashemi Dehkordi; Sara Khaheshi; Neda Mostofizadeh; Mahin Hashemipour
Journal:  Adv Biomed Res       Date:  2021-07-29

2.  Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Authors:  Phyllis W Speiser; Wiebke Arlt; Richard J Auchus; Laurence S Baskin; Gerard S Conway; Deborah P Merke; Heino F L Meyer-Bahlburg; Walter L Miller; M Hassan Murad; Sharon E Oberfield; Perrin C White
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 3.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

4.  Health problems of adolescent and adult patients with 21-hydroxylase deficiency.

Authors:  Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2018-10-30

5.  Clinical Patterns and Linear Growth in Children with Congenital Adrenal Hyperplasia, an 11-Year Experience.

Authors:  Adnan Al Shaikh; Yasser AlGhanmi; Saniah Awidah; Abdullah Bahha; Mohamed E Ahmed; Ashraf T Soliman
Journal:  Indian J Endocrinol Metab       Date:  2019 May-Jun

Review 6.  Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia.

Authors:  Mimi S Kim; Nicole R Fraga; Nare Minaeian; Mitchell E Geffner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-24       Impact factor: 5.555

7.  Epidemiology and Long-Term Adverse Outcomes in Korean Patients with Congenital Adrenal Hyperplasia: A Nationwide Study.

Authors:  Jung Hee Kim; Sunkyu Choi; Young Ah Lee; Juneyoung Lee; Sin Gon Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2022-02-28

8.  Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia.

Authors:  Ahmed Torky; Ninet Sinaii; Smita Jha; Jay Desai; Diala El-Maouche; Ashwini Mallappa; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2021-11-19       Impact factor: 5.958

9.  Disorders of sex development: a study of 194 cases.

Authors:  R Walia; M Singla; K Vaiphei; S Kumar; A Bhansali
Journal:  Endocr Connect       Date:  2018-01-31       Impact factor: 3.335

Review 10.  Caring for individuals with a difference of sex development (DSD): a Consensus Statement.

Authors:  Martine Cools; Anna Nordenström; Ralitsa Robeva; Joanne Hall; Puck Westerveld; Christa Flück; Birgit Köhler; Marta Berra; Alexander Springer; Katinka Schweizer; Vickie Pasterski
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.